Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 29;21(7):2360.
doi: 10.3390/ijms21072360.

Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma

Affiliations

Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma

Li-Han Lin et al. Int J Mol Sci. .

Abstract

Oral squamous cell carcinoma (OSCC) is a cancerous disease with poor prognosis. According to the statistics, the 5-year survival rate has not improved significantly over the past 20 years. The platelet-derived growth factor (PDGF) and its signaling pathway is a key regulator of angiogenesis and tumorigenesis. High level of PDGF and its receptor (PDGFR) have been reported in several types of malignancies. In this study, we investigated the relationship of the molecular expression levels of PDGF and PDGFR with clinicopathological parameters in OSCC. To this end, we measured the mRNA and protein levels of PDGF and PDGFR by real-time quantitative PCR (qRT-PCR), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA), respectively. We found positive correlations of the mRNA levels of PDGFA, PDGFB, and PDGFRB with lymph node metastasis and poor overall survival (OS). High expression of PDGF, PDGFRA, and PDGFRB were remarkably associated with lymph node metastasis and poor OS, as determined by immunohistochemistry. Preoperative serum levels of PDGF-AA and PDGF-BB had a positive correlation with preoperative platelet count. Elevated serum levels of PDGF-AA. PDGF-BB, and platelet count correlated with lymph node metastasis and an unfavorable outcome. In multivariate Cox regression analysis, PDGFA mRNA, PDGFB mRNA, PDGFRB mRNA, PDGF immunoexpression, PDGFRB immunoexpression, serum PDGF-AA, serum PDGF-BB, and platelet count emerged as significant independent prognostic factors for OS. In vitro, we found that elevated PDGF promotes colony formation, migration, and invasiveness of SAS and OECM-1 cancer cell lines. Our results suggest that the expression level of serum PDGF has the potential to become a useful diagnostic marker for the prognosis of OSCC. In addition, PDGFR should be considered as a potential therapeutic target for OSCC. Furthermore, research should be undertaken to elucidate the role of PDGF and PDGFR regarding the behavior of tumor cells in OSCC.

Keywords: oral squamous cell carcinoma; platelet-derived growth factor; platelet-derived growth factor receptor; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
mRNA expression profiles of matched non-cancerous oral mucosa, cancer, and lymph node metastatic tissues. Histograms showing the mRNA levels of PDGFA (A), PDGFB (B), PDGFRA (C), and PDGFRB (D) in matched non-cancerous oral mucosa, cancer, and lymph node metastatic tissues. The relative mRNA expression levels were calculated using the 2ΔΔCt method. ***, p < 0.001
Figure 2
Figure 2
Immunohistochemical staining in OSCC. (A,B) Immunohistochemistry of PDGF in adjacent normal looking mucosa (A) and OSCC tumors (B). (C,D) PDGFRA immunoexpression. (E,F) PDGFRB immunoexpression. All IHC images were photographed at 100× magnification.
Figure 3
Figure 3
Correlation between preoperative serum PDGF-AA, PDGF-BB, and platelet count. (A) Serum PDGF-AA levels are significantly positive correlated with the expression levels of PDGF-BB. (B,C) Serum PDGF-AA and PDGF-BB correlate positively with platelet count.
Figure 4
Figure 4
Kaplan–Meier analysis for overall patient survival according to mRNA expression of (A) PDGFA, (B) PDGFB, (C) PDGFRA, and (D) PDGFRB in OSCC. p-values were calculated by the log-rank test.
Figure 5
Figure 5
Kaplan–Meier analysis of OSCC patient survival according to predictive gene expression. (AC) Estimation of overall survival by immunohistochemical expression of PDGF (A), PDGFRA (B), and PDGFRB (C). (DF) Estimation of overall survival by preoperative serum levels of PDGF-AA (D), PDGF-BB (E), and platelet count (F).
Figure 6
Figure 6
Association between PDGF treatment and oncogenic phenotypes in HNSCC cells. (A) The effect of PEGF treatment on NOK, SAS, and OECM-1 cell proliferation was examined. (B) Anchorage-independent colony formation; (C) migration assay; and (D) invasion assay. *, p < 0.05; **, p < 0.01

References

    1. Health Promotion Administration, Ministry of Health and Welfare, Taiwan, Annual Report on the Causes of Death Statistics. [(accessed on 21 June 2019)];2018 Available online: https://www.mohw.gov.tw/dl-54578-bd0c9197-80ae-4cae-b015-0cb3a055a069.html.
    1. Gupta S., Kushwaha V.S., Verma S., Khan H., Bhatt M.L., Husain N., Negi M.P., Bhosale V.V., Ghatak A. Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation. Heliyon. 2016;2:e00206. doi: 10.1016/j.heliyon.2016.e00206. - DOI - PMC - PubMed
    1. Arantes L.M., de Carvalho A.C., Melendez M.E., Centrone C.C., Gois-Filho J.F., Toporcov T.N., Caly D.N., Tajara E.H., Goloni-Bertollo E.M., Carvalho A.L. Validation of methylation markers for diagnosis of oral cavity cancer. Eur. J. Cancer. 2015;51:632–641. doi: 10.1016/j.ejca.2015.01.060. - DOI - PubMed
    1. Dionne K.R., Warnakulasuriya S., Zain R.B., Cheong S.C. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int. J. Cancer. 2015;136:503–515. doi: 10.1002/ijc.28754. - DOI - PubMed
    1. Tanaka T., Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J. Oncol. 2011;2011:603740. doi: 10.1155/2011/603740. - DOI - PMC - PubMed

MeSH terms

Substances